Barostim is an implantable device that works by electrically stimulating carotid baroreceptors which increases baroreflex sensitivity, rebalances the autonomic nervous system and improves heart failure symptoms.
Barostim plus GDMT provides significant and meaningful improvements for heart failure patients beyond GDMT alone
Exercise capacity (6MHW): Patients with Barostim + GDMT were able to walk 44 meters farther than patients on GDMT alone at 12 months1
Quality of life (MLWHF): Barostim + GDMT patients had a 10-point improvement in quality of life scores than patients on GDMT alone at 24 months1
Functional status (NYHA class): 27% more patients improved at least 1 NYHA class at 24 months1
Freedom from all-cause death, LVAD, and transplant: Patients receiving Barostim + GDMT had a 34% reduction in all-cause death or the need for left ventricular assist device (LVAD) implantation or heart transplant at >4 years follow-up1
Zile MR, et al. Eur J Heart Fail. 2024 Apr 12
Barostim Indications
NYHA Class III or Class II (who had a recent history of Class III) despite treatment with guideline-directed medical therapies (medications and devices)*
LVEF < 35%
NT-proBNP < 1,600 pg/ML
*Guideline-directed medical therapy according to AHA/ACC/ESC guidelines
